Physician profile
Bailey Jo Mannis
NPI 1164017521
$3,526.11
in general payments reported to CMS, 2019-2025
36 companies · $965 in 2025
The $965 reported for 2025 was more than what 85% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $324 · 2023: $1,567 · 2024: $669 · 2025: $965.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,202.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,201.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $441.34 | 2023-2025 | Tecvayli, Rybrevant, Imbruvica |
| Regeneron Healthcare Solutions, INC. | $415.49 | 2022-2025 | Libtayo |
| Astrazeneca Pharmaceuticals Lp | $370.65 | 2022-2025 | Enhertu, Calquence, Imfinzi |
| Novartis Pharmaceuticals Corporation | $353.72 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $176.21 | 2023-2025 | Keytruda, Keytruda Qlex, Welireg |
| Gilead Sciences, INC. | $152.30 | 2023-2025 | Trodelvy |
| Lilly USA, LLC | $148.75 | 2022-2023 | Verzenio, Retevmo, Jaypirca |
| Daiichi Sankyo INC. | $132.73 | 2024-2025 | Enhertu, Vanflyta |
| Genzyme Corporation | $127.41 | 2022-2025 | |
| Stemline Therapeutics INC. | $125.00 | 2024 | Orserdu |
| Beigene USA, INC. | $107.02 | 2023-2024 | Brukinsa |
| Aveo Pharmaceuticals, INC. | $104.20 | 2023-2024 | Fotivda |
| Seagen INC. | $84.44 | 2023 | Padcev, Tukysa, Tivdak |
| Eisai INC. | $81.36 | 2023-2025 | |
| Pfizer INC. | $69.81 | 2024-2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $68.26 | 2022-2023 | Pemazyre, Monjuvi, Zynyz |
| Celgene Corporation | $58.80 | 2023-2024 | Pomalyst, Reblozyl |
| Tersera Therapeutics LLC | $52.47 | 2023-2024 | Zoladex |
| Takeda Pharmaceuticals U.S.A., INC. | $47.28 | 2023-2024 | Ninlaro |
| Bayer Healthcare Pharmaceuticals INC. | $37.51 | 2023 | |
| Adc Therapeutics America, INC. | $37.33 | 2023-2024 | |
| Alexion Pharmaceuticals, INC. | $34.05 | 2023-2024 | Ultomiris |
| Mirati Therapeutics, INC. | $30.85 | 2023 | Krazati |
| Deciphera Pharmaceuticals INC. | $26.90 | 2024 | Qinlock |
| Glaxosmithkline, LLC. | $26.17 | 2025 | Jemperli, Zejula |
| Array Biopharma INC | $23.99 | 2023 | Braftovi, Mektovi, Paxlovid |
| Beone Medicines USA, INC. | $23.64 | 2025 | Tevimbra |
| Astellas Pharma US INC | $20.85 | 2023 | Padcev |
| Taiho Oncology, INC. | $20.04 | 2023 | |
| Genentech USA, INC. | $19.85 | 2024 | Venclexta |
| E.R. Squibb & Sons, L.L.C. | $19.66 | 2023 | Opdivo |
| Pharmacosmos Therapeutics INC. | $19.50 | 2024 | Cosela |
| Abbvie INC. | $18.75 | 2023 | |
| Emd Serono, INC. | $18.71 | 2023 | Bavencio |
| Rigel Pharmaceuticals, INC. | $15.69 | 2023 | Tavalisse, Rezlidhia |
| Fennec Pharmaceuticals, INC. | $15.38 | 2025 | Fyarro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bailey Mannis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.